静脉ravulizumab治疗机械通气重症COVID-19的3期随机对照试验
该3期多中心开放标签随机对照试验纳入202例需机械通气的重症COVID-19患者,按2:1随机接受ravulizumab联合最佳支持治疗或单用最佳支持治疗。
要点
- ravulizumab联合BSC未改善重症COVID-19机械通气患者的29天生存。
- ravulizumab组感染和血管疾病不良事件发生率高于BSC组。
- C5抑制在重症患者中可行,但未转化为临床获益。
核心结论
- 在最佳支持治疗基础上加用ravulizumab未改善生存或其他次要结局。
- 安全性结果与ravulizumab已知安全性特征一致。
- 研究因中期分析无效而提前终止。
研究设计与样本
- 3期、多中心、开放标签、随机对照试验(ALXN1210-COV-305),纳入法国、日本、西班牙、英国和美国31家医院的成人患者。
- 202例患者随机分配,201例纳入意向治疗人群(ravulizumab+BSC组135例,BSC组66例)。
- 按插管状态分层,2:1随机分配至ravulizumab+BSC或单用BSC。
主要发现
- ravulizumab+BSC组127例中113例(89%)发生治疗中出现的不良事件,BSC组67例中56例(84%)。
- 感染和寄生虫感染在ravulizumab+BSC组73例(57%)vs BSC组24例(36%);血管疾病39例(31%)vs 12例(18%)。
- 5例患者发生被认为与ravulizumab相关的严重不良事件:菌血症、血小板减少、食管出血、隐球菌肺炎和发热各1例。
临床怎么用
- 不推荐对需机械通气的重症COVID-19患者常规使用ravulizumab。
- 使用ravulizumab时需警惕感染和血管疾病不良事件。
局限性
- 试验因无效提前终止,样本量有限。
- 开放标签设计可能影响不良事件报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The complement pathway is a potential target for the treatment of severe COVID-19. We evaluated the safety and efficacy of ravulizumab, a terminal complement C5 inhibitor, in patients hospitalised with severe COVID-19 requiring invasive or non-invasive mechanical ventilation. METHODS: This phase 3, multicentre, open-label, randomised controlled trial (ALXN1210-COV-305) enrolled adult patients (aged ≥18 years) from 31 hospitals in France, Japan, Spain, the UK, and the USA. Eligible patients had a confirmed diagnosis of SARS-CoV-2 that required hospitalisation and either invasive or non-invasive mechanical ventilation, with severe pneumonia, acute lung injury, or acute respiratory distress syndrome confirmed by CT scan or x-ray. We randomly assigned participants (2:1) to receive intravenous ravulizumab plus best supportive care (BSC) or BSC alone using a web-based interactive response system. Randomisation was in permuted blocks of six with stratification by intubation status. Bodyweight-based intravenous doses of ravulizumab were administered on days 1, 5, 10, and 15. The primary efficacy endpoint was survival based on all-cause mortality at day 29 in the intention-to-treat (ITT) population. Safety endpoints were analysed in all randomly assigned patients in the ravulizumab plus BSC group who received at least one dose of ravulizumab, and in all randomly assigned patients in the BSC group. The trial is registered with ClinicalTrials.gov, NCT04369469, and was terminated at interim analysis due to futility. FINDINGS: Between May 10, 2020, and Jan 13, 2021, 202 patients were enrolled in the study and randomly assigned to ravulizumab plus BSC or BSC. 201 patients were included in the ITT population (135 in the ravulizumab plus BSC group and 66 in the BSC group). The ravulizumab plus BSC group comprised 96 (71%) men and 39 (29%) women with a mean age of 63·2 years (SD 13·23); the BSC group comprised 43 (65%) men and 23 (35%) women with a mean age of 63·5 years (12·40). Most patients (113 [84%] of 135 in the ravulizumab plus BSC group and 53 [80%] of 66 in the BSC group) were on invasive mechanical ventilation at baseline. Overall survival estimates based on multiple imputation were 58% for patients receiving ravulizumab plus BSC and 60% for patients receiving BSC (Mantel-Haenszel analysis: risk difference -0·0205; 95% CI -0·1703 to 0·1293; one-sided p=0·61). In the safety population, 113 (89%) of 127 patients in the ravulizumab plus BSC group and 56 (84%) of 67 in the BSC group had a treatment-emergent adverse event. Of these events, infections and infestations (73 [57%] vs 24 [36%] patients) and vascular disorders (39 [31%] vs 12 [18%]) were observed more frequently in the ravulizumab plus BSC group than in the BSC group. Five patients had serious adverse events considered to be related to ravulizumab. These events were bacteraemia, thrombocytopenia, oesophageal haemorrhage, cryptococcal pneumonia, and pyrexia (in one patient each). INTERPRETATION: Addition of ravulizumab to BSC did not improve survival or other secondary outcomes. Safety findings were consistent with the known safety profile of ravulizumab in its approved indications. Despite the lack of efficacy, the study adds value for future research into complement therapeutics in critical illnesses by showing that C5 inhibition can be accomplished in severely ill patients. FUNDING: Alexion, AstraZeneca Rare Disease.
引用
- Annane D, Pittock SJ, Kulkarni HS, et al. Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2023. PMID: 36958364. doi:10.1016/S2213-2600(23)00082-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。